Bioinformatics Market

The global bioinformatics market is projected to reach USD 34.41 billion by 2031, up from USD 18.63 billion in 2026, at a CAGR of 13.1% from 2026 to 2031. This growth is driven by the increasing adoption of next-generation sequencing (NGS), expanding applications of genomics and multi-omics research, and rising demand for data-driven approaches in drug discovery, precision medicine, and clinical diagnostics. Rapid growth in biological data generated by high-throughput sequencing technologies, coupled with advances in artificial intelligence (AI), machine learning (ML), and cloud computing, is accelerating the adoption of bioinformatics solutions across pharmaceutical and biotechnology companies, academic and research institutes, hospitals, and contract research organizations (CROs).

The bioinformatics market is dominated by key players. The major players operating in this market are Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Revvity, Inc. (US), Eurofins Scientific (Luxembourg), BGI Genomics (China), Waters Corporation (US), DNAnexus, Inc. (US), Oxford Nanopore Technologies plc. (UK), 10x Genomics (US), PacBio (US), Dotmatics (US), and SOPHiA GENETICS (US).

To know about the assumptions considered for the study download the pdf brochure

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. is a leading provider of analytical instruments, life sciences solutions, specialty diagnostics, and laboratory services, with a strong presence in the bioinformatics market. The company serves pharmaceutical and biotechnology companies, academic and research institutions, clinical laboratories, healthcare providers, and government organizations worldwide. Its extensive portfolio of genomics, proteomics, and molecular biology solutions supports a wide range of bioinformatics applications, including next-generation sequencing (NGS), precision medicine, biomarker discovery, drug development, and clinical research. By leveraging advanced bioinformatics software, cloud-based informatics platforms, artificial intelligence, and high-performance computing, Thermo Fisher enables efficient analysis, interpretation, and management of large-scale omics data. The company's continued focus on innovation and strategic collaborations enhances its ability to deliver integrated bioinformatics solutions that improve data accuracy, optimize laboratory workflows, accelerate genomic research, and support informed decision-making across research and clinical settings.

Illumina, Inc. 

Illumina, Inc. is a global leader in DNA sequencing and array-based technologies, providing integrated genomics and bioinformatics solutions for research and clinical applications. The company offers a comprehensive portfolio of next-generation sequencing (NGS) platforms, reagents, microarrays, and bioinformatics software that support genomic analysis, precision medicine, oncology, reproductive health, infectious disease research, and population genomics. The company focuses on continuous innovation, strategic collaborations, and the expansion of its cloud-based bioinformatics ecosystem to strengthen its leadership in genomics and precision medicine. Illumina has also established partnerships with leading healthcare providers, research organizations, and technology companies to accelerate the adoption of genomics in clinical diagnostics and drug discovery. These initiatives enhance data accessibility, improve analytical accuracy, and streamline genomic workflows, supporting applications ranging from biomarker discovery and clinical research to personalized medicine and population-scale sequencing.

QIAGEN N.V.

QIAGEN N.V. is a global provider of sample and assay technologies, molecular diagnostics, and bioinformatics solutions, serving pharmaceutical and biotechnology companies, clinical laboratories, academic and research institutions, healthcare organizations, and government agencies worldwide. The company's comprehensive portfolio includes sample preparation technologies, molecular testing solutions, next-generation sequencing (NGS) workflows, PCR-based assays, and bioinformatics software that support applications in oncology, infectious diseases, inherited disorders, companion diagnostics, biomarker discovery, and precision medicine. The company focuses on continuous innovation, strategic partnerships, and digital transformation to strengthen its position in the global bioinformatics market. Its bioinformatics portfolio integrates cloud-based informatics platforms, genomic interpretation software, curated knowledge bases, and AI-enabled data analysis tools to enable efficient analysis, interpretation, and management of complex genomic and molecular data. QIAGEN's bioinformatics solutions are designed to streamline laboratory workflows, enhance the accuracy of genomic interpretation, and support data-driven clinical and research decision-making.

Related Reports:

Bioinformatics Market by Offering [Software (Genomics, Multiomics, Proteomics), Services (Analysis, Sequencing)], Function (Variant & Structural Analysis), Use Case (Drug Discovery, Biomarker), End User (Pharma & Biotech, CROs) - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]